Researchers at Stanford have developed a new method for using bacterial lipoproteins as nanocarriers for small molecule drugs, opening the door to a novel class of biodegradable, protein-based drug delivery vehicles.
Researchers at Stanford have developed an IL-7–conjugated lipid nanoparticle (LNP) platform designed to substantially improve mRNA delivery to T cells for direct in vivo T-cell engineering.
Stanford researchers have developed a next-generation programmable transcriptional activation platform, TIGRa, that addresses key limitations of CRISPRa technologies, including large size, limited multiplexing capacity, and delivery constraints.
Researchers at Stanford University have developed a compact insulin pump for continuous subcutaneous insulin infusion (CSII) that addresses a core limitation of many commercial pumps: device size driven by piston-based mechanics.
The blood-brain barrier (BBB) remains a major obstacle to developing effective therapies for neurological and neurodegenerative disease, because most drugs and biologics do not efficiently reach brain tissue.
Stanford researchers have developed a macrophage-targeted PEGylated liposome ("PEGosome") platform that selectively delivers polyethylene glycol (PEG) to inflammatory monocytes and macrophages driving neuroinflammation in diseases such as multiple sclerosis (MS), Alzheimer's d
Researchers at Stanford University have demonstrated rapid and accurate identification of extracellular vesicles (EVs) from different cell lines using an AI-assisted optical platform.
Stanford scientists have discovered that Guanidinylated Serinol Charge-altering Releasable Transporters (GSer-CARTs) can be tuned for selective mRNA delivery to the lung and spleen in a predictable fashion.
Researchers at Stanford have developed a novel strategy to enhance vaccine efficacy using mRNA lipid nanoparticles (LNPs) encoding immunostimulatory cytokines.
Stanford researchers have repurposed two existing drugs and created a combined nanoparticle formulation that provides both intraocular pressure management and neuroprotection for glaucoma therapy.
Stanford scientists have developed a prolonged drug-releasing formulation for delivering an iron chelation therapeutic to central nervous system in preterm births to prevent post-hemorrhagic hydrocephalus (PHH) in severe neonatal intraventricular hemorrhage (IVH)
Stanford researchers have created an optimized stuffer sequence derived from the human BMP-10 3'UTR to enhance the packaging efficiency, productivity, and safety of recombinant adeno-associated virus (rAAV) vectors in gene therapy applications.